Cell-Cycle Dependent Expression of a Translocation-Mediated Fusion Oncogene Mediates Checkpoint Adaptation in Rhabdomyosarcoma

PLoS Genetics

Volumn 10, Issue 1, 2014, Pages

  Kikuchi, Ken ^a   Hettmer, Simone ^b,c,i   Aslam, M Imran ^a   Michalek, Joel E ^d   Laub, Wolfram ^e   Wilky, Breelyn A ^f   Loeb, David M ^g   Rubin, Brian P ^h   Wagers, Amy J ^b,i   Keller, Charles ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Harvard University   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h TAUSSIG CANCER INSTITUTE   (United States)

ⁱ JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEACHING; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL SPECIFICITY; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINESIS; EVOLUTIONARY ADAPTATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE FUSION; GENE LOCUS; GENE TRANSLOCATION; GENETIC ENGINEERING; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PAX3 FOXO1A FUSION GENE; PROTEIN DEGRADATION; RHABDOMYOSARCOMA; RNA INTERFERENCE;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; RADIATION; RHABDOMYOSARCOMA; TRANSLOCATION, GENETIC;

EID: 84896690221     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004107     Document Type: Article

References (38)

1. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, et al. (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 21: 78-84.
2. Anderson JR, Barr FG, Hawkins DS, Parham DM, Skapek SX, et al. (2010) Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature. J Clin Oncol 28: e587-588; author reply e589-590.
3. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, et al. (2010) Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28: 2151-2158.
4. Wexler LH, Ladanyi M, (2010) Diagnosing alveolar rhabdomyosarcoma: morphology must be coupled with fusion confirmation. J Clin Oncol 28: 2126-2128.
5. Keller C, Arenkiel BR, Coffin CM, El-Bardeesy N, DePinho RA, et al. (2004) Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 18: 2614-2626.
6. Keller C, Hansen MS, Coffin CM, Capecchi MR, (2004) Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 18: 2608-2613.
7. Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, et al. (2009) Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res 69: 2902-2911.
8. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, et al. (2008) PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 27: 6550-6560.
9. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, et al. (2010) Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer. Cancer Res 70: 6497-508.
10. Osuka S, Sampetrean O, Shimizu T, Saga I, Onishi N, et al. (2013) IGF1 receptor signaling regulates adaptive radioprotection in glioma stem cells. Stem cells 31: 627-640.
11. Nurse P, (1994) Ordering S phase and M phase in the cell cycle. Cell 79: 547-550.
12. Berry LD, Gould KL, (1996) Regulation of Cdc2 activity by phosphorylation at T14/Y15. Progress in cell cycle research 2: 99-105.
13. Syljuasen RG, Jensen S, Bartek J, Lukas J, (2006) Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. Cancer Res 66: 10253-10257.
14. Syljuasen RG, (2007) Checkpoint adaptation in human cells. Oncogene 26: 5833-5839.
15. Yoo HY, Kumagai A, Shevchenko A, Shevchenko A, Dunphy WG, (2004) Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase. Cell 117: 575-588.
16. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, et al. (2010) Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 70: 6497-6508.
17. Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, et al. (2012) An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochem Biophys Res Commun 426: 363-368.
18. Kitzmann M, Carnac G, Vandromme M, Primig M, Lamb NJ, et al. (1998) The muscle regulatory factors MyoD and myf-5 undergo distinct cell cycle-specific expression in muscle cells. J Cell Biol 142: 1447-1459.
19. Batonnet-Pichon S, Tintignac LJ, Castro A, Sirri V, Leibovitch MP, et al. (2006) MyoD undergoes a distinct G2/M-specific regulation in muscle cells. Exp Cell Res 312: 3999-4010.
20. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ, (2001) Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20: 7453-7463.
21. Clemenson C, Marsolier-Kergoat MC, (2009) DNA damage checkpoint inactivation: adaptation and recovery. DNA Repair (Amst) 8: 1101-1109.
22. Hanks S, Coleman K, Reid S, Plaja A, Firth H, et al. (2004) Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 36: 1159-1161.
23. Kowal-Vern A, Gonzalez-Crussi F, Turner J, Trujillo YP, Chou P, et al. (1990) Flow and image cytometric DNA analysis in rhabdomyosarcoma. Cancer Res 50: 6023-6027.
24. San Miguel-Fraile P, Carrillo-Gijon R, Rodriguez-Peralto JL, Badiola IA, (2004) Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in childhood rhabdomyosarcoma. Am J Clin Pathol 121: 358-365.
25. Shapiro DN, Parham DM, Douglass EC, Ashmun R, Webber BL, et al. (1991) Relationship of tumor-cell ploidy to histologic subtype and treatment outcome in children and adolescents with unresectable rhabdomyosarcoma. J Clin Oncol 9: 159-166.
26. Li G, Kikuchi K, Radka M, Abraham J, Rubin BP, et al. (2013) IL-4 receptor blockade abrogates satellite cell- rhabdomyosarcoma fusion and prevents tumor establishment. Stem cells 31: 2304-12.
27. Weihua Z, Lin Q, Ramoth AJ, Fan D, Fidler IJ, (2011) Formation of solid tumors by a single multinucleated cancer cell. Cancer 117: 4092-4099.
28. Kikuchi K, Soundararajan A, Zarzabal LA, Weems CR, Nelon LD, et al. (2012) Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 32: 286-95.
29. Yamada HY, Rao CV, (2010) Genes that modulate the sensitivity for anti-microtubule drug-mediated chemotherapy. Curr Cancer Drug Targets 10: 623-633.
30. Hu K, Lee C, Qiu D, Fotovati A, Davies A, et al. (2009) Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 8: 3024-3035.
31. Skapek SX, Anderson J, Barr FG, Bridge JA, Gastier-Foster JM, et al. (2013) PAX-FOXO1 Fusion Status Drives Unfavorable Outcome for Children With Rhabdomyosarcoma: A Children's Oncology Group Report. Pediatr Blood Cancer 60: 1411-7.
32. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, et al. (2012) PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 30: 1670-1677.
33. Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, et al. (2012) Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer 118: 1130-1137.
34. Haldar M, Hancock JD, Coffin CM, Lessnick SL, Capecchi MR, (2007) A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 11: 375-388.
35. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, et al. (2009) Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A 106: 2712-2716.
36. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, et al. (2011) MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20: 66-78.
37. DiMartino JF, Miller T, Ayton PM, Landewe T, Hess JL, et al. (2000) A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 96: 3887-3893.
38. Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, et al. (2008) RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111: 2238-2245.